Dynavax Technologies Corporation (NASDAQ:DVAX) surged 8% Thursday following the announcement of encouraging topline data from ...

Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's ...

Results from the first part of a Phase I/II trial (NCT06569823) showed that Z-1018 generated immune responses comparable to ...

Dynavax Technologies has revealed promising topline outcomes from the initial part of its Phase I/II clinical trial, ...

The Emeryville, California-based biotech has just released topline results from a phase 1/2 head-to-head study comparing its ...

Shares of Dynavax rose after the company released positive results from a trial of its shingles vaccine tested against current Shingles vaccine Shingrix. The stock was up 6.7% to $11.12 but is still ...

Dynavax (DVAX) stock gains as the company's Z-1018 shingles shot shows immune response comparable to GSK's (GSK) Shingrix vaccine in a Phase 1/2 trial. Read more here.

Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025.

Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase ...

Shares in Dynavax Technologies Corporation closed 5% higher Thursday after the presentation of positive top-line results from ...

Key Points Dynavax Technologies (NASDAQ:DVAX) exceeded analyst expectations in Q2 2025, reporting GAAP revenue of $95.4 million and GAAP diluted EPS of $0.14. HEPLISAV-B, Dynavax's two-dose adult ...

The company said that it now intends to advance Z-1018 into the next part of the study in adults 70 years of age and older in ...